Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5282272
Max Phase: Preclinical
Molecular Formula: C17H11BrClN3O3
Molecular Weight: 420.65
Associated Items:
ID: ALA5282272
Max Phase: Preclinical
Molecular Formula: C17H11BrClN3O3
Molecular Weight: 420.65
Associated Items:
Canonical SMILES: Cc1nc2ccc(Br)cc2c(=O)n1/C=C/c1ccc(Cl)c([N+](=O)[O-])c1
Standard InChI: InChI=1S/C17H11BrClN3O3/c1-10-20-15-5-3-12(18)9-13(15)17(23)21(10)7-6-11-2-4-14(19)16(8-11)22(24)25/h2-9H,1H3/b7-6+
Standard InChI Key: JTQZAHSOYIEGCB-VOTSOKGWSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 420.65 | Molecular Weight (Monoisotopic): 418.9672 | AlogP: 4.66 | #Rotatable Bonds: 3 |
Polar Surface Area: 78.03 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 4.64 | CX LogP: 4.42 | CX LogD: 4.42 |
Aromatic Rings: 3 | Heavy Atoms: 25 | QED Weighted: 0.46 | Np Likeness Score: -1.22 |
1. Alagarsamy V, Chitra K, Saravanan G, Solomon VR, Sulthana MT, Narendhar B.. (2018) An overview of quinazolines: Pharmacological significance and recent developments., 151 [PMID:29656203] [10.1016/j.ejmech.2018.03.076] |
Source(1):